Lilly Announces Results From SURMOUNT-1 Three-Year Study Of Tirzepatide, Showing Weekly Tirzepatide Injections Reduced Risk Of Progression To Type 2 Diabetes By 94% In Adults With Pre-Diabetes And Obesity
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's SURMOUNT-1 study reveals that weekly injections of Tirzepatide significantly reduce the risk of progression to Type 2 diabetes by 94% in adults with pre-diabetes and obesity.
August 20, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's SURMOUNT-1 study demonstrates that Tirzepatide injections reduce the risk of Type 2 diabetes by 94% in adults with pre-diabetes and obesity, potentially boosting the company's market position in diabetes treatment.
The significant reduction in diabetes risk positions Tirzepatide as a leading treatment option, likely enhancing Eli Lilly's competitive edge and market share in the diabetes treatment sector. This positive clinical outcome is expected to drive investor confidence and potentially increase LLY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100